Clinical Trial Update: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bleselumab for preventing recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Bleselumab

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Status: COMPLETED | Results posted: 2022-01-05